Register now to R3i !
Your Login
Your Password
Confirm Password  
Your Email

Microvascular Residual Risk THROUGH LANDMARK STUDY

1 March 2011
The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Trial

Costa J, Borges M, David C, Vaz Carneiro A. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials. BMJ 2006;332:1115-24.

The ACCORD Study Group and ACCORD Eye Study Group
Summary
Comments & References
STUDY SUMMARY
Objective: To evaluate the effects of specific strategies for managing blood glucose levels, serum lipid levels, and blood pressure on the development and progression of diabetic retinopathy in participants with type 2 diabetes and additional cardiovascular risk factors.
Population:
  • A subgroup of 2,856 participants of the main ACCORD trial evaluable for the effects of the study intervention on progression of diabetic retinopathy.
  • Age range: 40-79 years if evidence of clinical CVD, 55-79 years if at risk of CVD.
Main inclusion criteria
  • For all participants:
    • Type 2 diabetes.
    • HbA1c ≥7.5%.
    • Pre-existing CV or atherosclerotic disease or high risk of CV disease.
  • For participation in the blood pressure control arm:
    • SBP between 130 and 180 mmHg.
  • For participation in the lipid control arm:
    • LDL-C between  60 and 180 mg/dL (1.55‑4.65 mmol/L).
    • HDL-C <55 mg/dl (1.42 mmol/l) in women or blacks, <50 mg/dL (1.29 mmol/L) in others.
    • TG <750 mg/dL (8.5 mmol/L) if not receiving lipid-lowering therapy; <400 mg/dL (4.5 mmol/L) on lipid-lowering therapy.
Main exclusion criteria
  • Frequent or recent hypoglycemic events
  • BMI >45 kg/m2.
  • Serum creatinine >1.5 mg/dL.
  • Proliferative diabetic retinopathy treated with laser photocoagulation and/or vitrectomy.
Interventions
  • All ACCORD Eye participants (n=2,856) were randomized to intensive glycemic control (targeting HbA1c <6.0%; n=1,429) or standard glycemic control (targeting HbA1c 7.0–7.9%; n=1,427).
  • Of these 2,856 participants:
    • 1593 patients were randomized in a 2x2 factorial design to simvastatin plus fenofibrate (160 mg/day, adjusted according to glomerular filtration, n=806) or simvastatin plus matching placebo (n=787).
    • 1263 patients were randomized in a 2x2 factorial design to intensive BP control (targeting systolic blood pressure [SBP] <120 mm Hg; n=647) or standard BP control (targeting SBP <140 mm Hg; n=616).
Primary outcome
  • A composite endpoint of either progression of diabetic retinopathy by ≥3 steps on the Early Treatment Diabetic Retinopathy Study (ETDRS) severity scale or development of proliferative diabetic retinopathy necessitating photocoagulation therapy or vitrectomy.
  • Eye examinations and fundus photographs were done at baseline and Year 4.
Secondary outcomes
  • Treatment effects on moderate vision loss (worsening by 3 or more lines on ETDRS visual acuity chart.
  • 28 pre-specified subgroup analyses, including tertile analysis of baseline LDL-C, TG, and HDL-C and analysis of patients with both elevated TG and low HDL-C at baseline (i.e. atherogenic dyslipidemia) versus others.
Study design Randomized multicentre study, incorporating two 2 x 2 factorial treatment arms.
Follow up duration:

4.7 years for the primary outcome and 5 years for all deaths.

Methods:
  • Standardized eye examination and fundus photography at baseline and at year 4.
  • Photos graded based on the modified ETDRS Final Retinopathy Severity Scale for Persons (where Step 1= no retinopathy in either eye and Step 17= high-risk proliferative retinopathy).
  • Information on laser photocoagulation and vitrectomy collected at each annual visit.
  • Time to event methods, ITT analysis.  
Main results:

Glycemic control arm

  • Significant 33% reduction in relative risk of progression of diabetic retinopathy in the intensive glycemic control group (P = 0.003) (Table 1).
  • However, after a mean 3.5-year follow-up, early termination due to significant excess all-cause mortality (257 deaths) in the intensive-therapy group, as compared with 203 in the standard therapy group (P = 0.04).  

Blood pressure arm

  • Non-significant 23% increase in relative risk of progression of diabetic retinopathy in the intensive blood pressure control group (P = 0.29).

Lipid arm

  • Significant 40% decrease in relative risk of progression of diabetic retinopathy in the fenofibrate plus simvastatin group (P = 0.006).
  • Effect independent from control of LDL-C, glycemia and blood pressure.
  • No significant interaction between participants with and without atherogenic dyslipidemia at baseline.
There was no significant effect of any of the 3 interventions on moderate vision loss.
Author's conclusion: Intensive glycemic control and intensive combination treatment of dyslipidemia, but not intensive blood pressure control, reduced the rate of progression of diabetic retinopathy.

COMMENT

ACCORD Eye1 was a substudy of the main ACCORD trial,2 in which 3 interventions were evaluated in patients with type 2 diabetes and additional cardiovascular risk factors according to a factorial design. Intensive vs. standard glycemic control was compared in all patients, whereas intensive vs. standard blood pressure control, and simvastatin-fenofibrate combination vs. simvastatin plus placebo were compared in two subsets of these patients. The ACCORD Eye substudy evaluated the effect of the 3 interventions on progression of diabetic retinopathy.

In ACCORD Eye, intensive glycemic control significantly reduced by 33% (p=0.03) progression of diabetic retinopathy.1 This was, however, associated with an unexpected and major drawback: an excess of all-cause deaths in the intensive glycemic control group led to the premature termination of the ACCORD glycemic arm.3 Subsequently, standard glycemic control was adopted for all ACCORD participants. The reasons for this excess mortality are not clear. A comparison with the ADVANCE trial,4 in which intensive glycemic control using a fixed combination of an ACE (perindopril) with a diuretic (indapamide) was not associated with an increased rate of deaths suggests that this adverse outcome might be treatment-dependent. Another difference between these two trials is that no reduction in diabetic retinopathy was seen in the ADVANCE trial.4

Another and rather unexpected result of ACCORD Eye was the lack of beneficial effect of intensive blood pressure control aiming at blood pressure normalization on diabetic retinopathy progression. In the United Kingdom Prospective Diabetes Study (UKPDS),5 conducted in patients with newly-diagnosed type 2 diabetes, tight blood pressure control slowed progression of retinopathy after 6 years of treatment. Whether a longer duration of intensive blood pressure therapy might have resulted in a significant impact on progression of diabetic retinopathy in the ACCORD Eye study remains speculative. It is also noteworthy that both baseline and achieved blood pressure levels were much higher in the UKPDS trial. 

Finally, progression of diabetic retinopathy was significantly reduced by 40% (P=0.006) in patients treated with a simvastatin-fenofibrate combination compared with those treated with simvastatin plus placebo.  Such a beneficial effect was achieved on top of well-controlled LDL-C, glycemia and systolic blood pressure. The simvastatin-fenofibrate combination was well tolerated. In particular, muscle toxicity was rare and not more frequent in patients treated with the combination than in those treated with simvastatin alone.

There were no significant interactions between the effect of fenofibrate and any of the prespecified characteristics in subgroup analyses. In particular, fenofibrate reduced diabetic retinopathy independently of LDL-C, HDL-C and TG levels. This contrasts with another publication stemming from the ACCORD trial: in ACCORD Lipid,6 fenofibrate reduced macrovascular events only in those patients with diabetes who had baseline atherogenic dyslipidemia (defined as TG>204 and HDL<42 mg/dL); in ACCORD Eye, a prespecified subgroup analysis showed no significant interaction between the presence or absence of atherogenic dyslipidemia on the changes in progression of diabetic retinopathy in patients treated with fenofibrate.1

It must be emphasized that about 50% of participants in the ACCORD Eye lipid arm had already signs or symptoms of diabetic retinopathy at baseline, and were therefore in secondary microvascular prevention. The apparent interaction between treatment and presence or diabetic retinopathy at baseline (P=0.03) did not remain significant after multivariate analysis.

ACCORD Eye results confirm the benefit of fenofibrate on diabetic eye disease seen in the FIELD study.7 In a FIELD sub-analysis, fenofibrate reduced the rate of laser treatment by 37%. In ACCORD Eye, fenofibrate reduced the rate of progression of diabetic retinopathy by 40%.

ACCORD Eye had an appropriate design for a residual vascular risk reduction trial. Indeed, the treatments used in ACCORD Eye targeted three major modifiable macrovascular risk factors in patients with diabetes. The reduction of diabetic retinopathy by fenofibrate was seen in patients with LDL-C, blood glucose, and blood pressure at or near goal according to current clinical practice guidelines. Furthermore, the residual risk of diabetic retinopathy was safely and effectively addressed by fenofibrate in patients with a broad range of triglycerides and HDL-C levels. In ACCORD Eye, fenofibrate appeared effective in preventing progression of diabetic retinopathy irrespective of baseline non-LDL lipids, and with a lower number-needed-to-treat figure than intensive glycemic control, the latter otherwise associated with significant higher all-cause mortality.

 

* The Early Treatment Diabetic Retinopathy Study (ETDRS) classification comprises six categories of increasing diabetic retinopathy severity: (1) clinically absent diabetic retinopathy, (2) mild to moderate nonproliferative diabetic retinopathy (NPDR), (3) moderate to severe NPDR, (4) severe NPDR, (5) very severe NPDR, and (6) proliferative diabetic retinopathy (PDR).8


References
  1. Chew EY, et al.; ACCORD Study Group and ACCORD Eye Study Group. Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes. N Engl J Med 2010;363:233-44.
  2. Buse JB, et al.; ACCORD Study Group. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol 2007;99:21i-33i.
  3. Gerstein HC, et al.;  ACCORD Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.
  4. Patel A, et al.; ADVANCE Collaborative Group. Intensive blood glucose control and  vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.
  5. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Brit Med J 1998;317:703-13.
  6. Ginsberg HN, et al.;  ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74.
  7.  Keech A, et al; The FIELD study investigators. Effect of long‐term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849‐61.
Key words Type 2 Diabetes – Microvascular Residual Risk – Diabetic retinopathy – Atherogenic dyslipidemia – Fenofibrate – Simvastatin